Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.42
VOLC's Cash to Debt is ranked higher than
55% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. VOLC: 0.42 )
VOLC' s 10-Year Cash to Debt Range
Min: 0.25   Max: No Debt
Current: 0.42

Equity to Asset 0.35
VOLC's Equity to Asset is ranked higher than
50% of the 448 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. VOLC: 0.35 )
VOLC' s 10-Year Equity to Asset Range
Min: -0.89   Max: 0.88
Current: 0.35

-0.89
0.88
F-Score: 3
Z-Score: 1.13
M-Score: -2.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -6.96
VOLC's Operating margin (%) is ranked higher than
60% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 5.53 vs. VOLC: -6.96 )
VOLC' s 10-Year Operating margin (%) Range
Min: -25.38   Max: 7.4
Current: -6.96

-25.38
7.4
Net-margin (%) -9.83
VOLC's Net-margin (%) is ranked higher than
59% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 3.93 vs. VOLC: -9.83 )
VOLC' s 10-Year Net-margin (%) Range
Min: -64.36   Max: 11.09
Current: -9.83

-64.36
11.09
ROE (%) -12.01
VOLC's ROE (%) is ranked higher than
59% of the 437 Companies
in the Global Medical Devices industry.

( Industry Median: 5.17 vs. VOLC: -12.01 )
VOLC' s 10-Year ROE (%) Range
Min: -21.58   Max: 12.42
Current: -12.01

-21.58
12.42
ROA (%) -4.51
VOLC's ROA (%) is ranked higher than
63% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. VOLC: -4.51 )
VOLC' s 10-Year ROA (%) Range
Min: -165.23   Max: 8.21
Current: -4.51

-165.23
8.21
ROC (Joel Greenblatt) (%) -12.96
VOLC's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 466 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. VOLC: -12.96 )
VOLC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -132.71   Max: 19.72
Current: -12.96

-132.71
19.72
Revenue Growth (%) 9.50
VOLC's Revenue Growth (%) is ranked higher than
82% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. VOLC: 9.50 )
VOLC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 20.2
Current: 9.5

0
20.2
EBITDA Growth (%) -54.50
VOLC's EBITDA Growth (%) is ranked higher than
50% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: -0.70 vs. VOLC: -54.50 )
VOLC' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -7.3
Current: -54.5

» VOLC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

VOLC Guru Trades in Q4 2013

Steven Cohen 194,900 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 4,663,127 sh (-2.95%)
Mariko Gordon 390,163 sh (-84.95%)
» More
Q1 2014

VOLC Guru Trades in Q1 2014

Steven Cohen 33,418 sh (New)
Mariko Gordon Sold Out
Manning & Napier Advisors, Inc 3,958,382 sh (-15.11%)
» More
Q2 2014

VOLC Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 4,733,937 sh (+19.59%)
Steven Cohen 426,000 sh (unchged)
» More
Q3 2014

VOLC Guru Trades in Q3 2014

Jim Simons 408,766 sh (New)
Paul Tudor Jones 15,981 sh (New)
Manning & Napier Advisors, Inc 5,961,507 sh (+25.93%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with VOLC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2014-03-31 Sold Out 0.35%$19.33 - $23.22 $ 11.22-48%0
Mariko Gordon 2013-12-31 Reduce -84.95%2.38%$18.95 - $24.36 $ 11.22-49%390163
Mariko Gordon 2013-09-30 Add 6.94%0.18%$18.04 - $23.99 $ 11.22-47%2592784
Mariko Gordon 2013-06-30 New Buy2.1%$16.58 - $22.41 $ 11.22-41%2424563
George Soros 2011-12-31 Sold Out 0.03%$21.76 - $30.57 $ 11.22-54%0
George Soros 2011-09-30 Reduce -35.69%0.02%$26.22 - $33.51 $ 11.22-63%67200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.89
VOLC's P/B is ranked higher than
84% of the 506 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. VOLC: 1.89 )
VOLC' s 10-Year P/B Range
Min: 1.68   Max: 10.49
Current: 1.89

1.68
10.49
P/S 1.47
VOLC's P/S is ranked higher than
83% of the 506 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. VOLC: 1.47 )
VOLC' s 10-Year P/S Range
Min: 0.68   Max: 6.89
Current: 1.47

0.68
6.89
EV-to-EBIT -29.69
VOLC's EV-to-EBIT is ranked higher than
65% of the 506 Companies
in the Global Medical Devices industry.

( Industry Median: 78.19 vs. VOLC: -29.69 )
VOLC' s 10-Year EV-to-EBIT Range
Min: -2321.6   Max: 142
Current: -29.69

-2321.6
142
Current Ratio 3.56
VOLC's Current Ratio is ranked higher than
77% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. VOLC: 3.56 )
VOLC' s 10-Year Current Ratio Range
Min: 1.49   Max: 9.25
Current: 3.56

1.49
9.25
Quick Ratio 2.81
VOLC's Quick Ratio is ranked higher than
77% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. VOLC: 2.81 )
VOLC' s 10-Year Quick Ratio Range
Min: 1.01   Max: 8.31
Current: 2.81

1.01
8.31

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.69
VOLC's Price/Tangible Book is ranked higher than
58% of the 506 Companies
in the Global Medical Devices industry.

( Industry Median: 6.46 vs. VOLC: 19.69 )
VOLC' s 10-Year Price/Tangible Book Range
Min: 2.62   Max: 30.89
Current: 19.69

2.62
30.89
Price/DCF (Projected) 6.31
VOLC's Price/DCF (Projected) is ranked higher than
81% of the 506 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VOLC: 6.31 )
VOLC' s 10-Year Price/DCF (Projected) Range
Min: 4.52   Max: 15.29
Current: 6.31

4.52
15.29
Price/Median PS Value 0.38
VOLC's Price/Median PS Value is ranked higher than
97% of the 506 Companies
in the Global Medical Devices industry.

( Industry Median: 1.19 vs. VOLC: 0.38 )
VOLC' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 1.67
Current: 0.38

0.19
1.67
Earnings Yield (Greenblatt) -3.40
VOLC's Earnings Yield (Greenblatt) is ranked higher than
61% of the 454 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. VOLC: -3.40 )
VOLC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 2.4
Current: -3.4

0.7
2.4
Forward Rate of Return (Yacktman) -1.02
VOLC's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 343 Companies
in the Global Medical Devices industry.

( Industry Median: 0.71 vs. VOLC: -1.02 )
VOLC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.8   Max: -0.5
Current: -1.02

-4.8
-0.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:VQY.Germany
Volcano Corp incorporated in the state of Delaware in January 2000. The Company completed its initial public offering on June 15, 2006. The Company designs, develops, manufactures and commercializes a broad suite of precision guided therapy tools including intravascular ultrasound, or IVUS, and fractional flow reserve, or FFR, products. The IVUS products include single-procedure disposable phased array and rotational IVUS imaging catheters, and additional functionality options such as ChromaFlo stent apposition analysis. FFR offerings can be accessed through its multi-modality platforms, and it also provide FFR-only consoles. Its products include: IVUS Products, Catheters, its single-use disposable catheters operate and interface solely with its family of consoles. Catheters, its single-use disposable catheters operate and interface solely with its family of consoles. ChromaFlo stent apposition analysis technology uses sequential IVUS frames to differentiate circulating blood from stationary or anchored tissue. SyncVision, Sync-Rx Ltd, or Sync-Rx, an Israel-based company that develops advanced software applications designed to optimize and facilitate trans-catheter cardiovascular interventions using automated online image processing. FFR products consist of pressure and flow consoles and single-procedure disposable pressure and flow guide wires. The Company's primary imaging competitors globally are Boston Scientific, Inc., or Boston Scientific, with its IVUS offering and St. Jude Medical, Inc., or St. Jude with its OCT offering. In Japan, it also competes with Terumo Corporation, which offers both IVUS and OCT. In the FFR market, its primary competitor is St. Jude. Because of the size of the vascular market opportunities, competitors and potential competitors have dedicated and will continue to dedicate significant resources to aggressively promote their products. It has registered and common law trademarks in the U.S. and elsewhere in the world including, but not limited to, Aim, Axsun, Bi-Trieval, Centriq, ChromaFlo, ComboMap, ComboWire, Core, Crux, Crux Biomedical, Define, Eagle Eye, ETNA, FACT, FloMap, FloWire, Ginko, GlyDx, Hi-Q, iFR, In-Line Digital, Instant Wave-Free Ratio, Intentio, Octave, pcFM, Precision Guided Therapy, PreView, PrimeWire, PrimeWire Prestige, ReFlow, Revolution, SlyDx, s5i, SmartMap, SpinVision, Sync-Rx, Trak Back, Valet, Verrata, VH, VIBE, Virtual Histology, Visions, Volcano, Wavewire, Xtract and Zuum. The Company's medical device products are subject to extensive and rigorous regulation by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries.
» More Articles for VOLC

Headlines

Articles On GuruFocus.com
5-year lows: Hecla Mining Co, Comstock Resources Inc, Permian Basin Royalty Trust, and Volcano Corp. Nov 02 2014 
Weekly 3-Year Low Highlights: CHT, NE, HL, VOLC Sep 21 2014 
Who Is Mariko Gordon? A Guru to Follow Aug 30 2013 
Weekly Guru Bargains Highlights: GOLD, GFI, SAPMY, APPL, VOLC May 20 2013 
Weekly Guru Bargains Highlights: VOLC, SAPMY, BVN, NEM, TFM May 13 2013 
Weekly Guru Bargains Highlights: GOLD, NEM, ABX, VOLC, GFI May 06 2013 
Weekly 3-Year Low Highlights: PACT, ATI, VLY, VOLC Apr 28 2013 
Weekly Guru Bargains Highlights: AAPL, AEM, VOLC, ABX, TFM Apr 28 2013 
Volcano Corp. (VOLC) President & CEO R Scott Huennekens sells 37,500 Shares Mar 08 2011 
Volcano Corp. (VOLC) CFO John T Dahldorf sells 1,724 Shares Mar 01 2011 

More From Other Websites
Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast Nov 17 2014
Volcano Corp. (VOLC) Stock Higher Today After Analyst Upgrade Nov 17 2014
UPDATE: Credit Suisse Upgrades Volcano On Multiple Positive Factors Nov 17 2014
VOLCANO CORP Financials Nov 14 2014
Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low Nov 10 2014
10-Q for Volcano Corp. Nov 09 2014
VOLCANO CORP Files SEC form 10-Q, Quarterly Report Nov 07 2014
Volcano tops Street 3Q forecasts Nov 06 2014
Volcano tops Street 3Q forecasts Nov 06 2014
Volcano Corp Earnings Call scheduled for 5:00 pm ET today Nov 06 2014
VOLCANO CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 06 2014
Volcano Reports Third Quarter Results Nov 06 2014
Q3 2014 Volcano Corp Earnings Release - After Market Close Nov 06 2014
Volcano Corporation Presentation At Credit Suisse Conference To Be Webcast Nov 04 2014
Volcano Corporation Presentation At Credit Suisse Conference To Be Webcast Nov 04 2014
Call buyers bet Volcano will fire up Nov 04 2014
Volcano Corporation Schedules Third Quarter Conference Call, Webcast Oct 29 2014
Volcano Corporation Schedules Third Quarter Conference Call, Webcast Oct 29 2014
Volcano Corp Banks on IVUS Portfolio amid Several Odds Oct 13 2014
U.S. equities finish mixed Oct 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK